
    
      Following randomization, there will be 2 periods during the study:

        -  Conversion and Maintenance Period (Weeks 0 to 52): conversion to vadadustat TIW or to
           remain on MirceraÂ® (Weeks 0 to 20). There will be a primary efficacy evaluation period
           (Weeks 20 to 26) and a secondary efficacy evaluation period (Weeks 46 to 52).

        -  Safety Follow-up Period (Early Termination [ET] and Follow-Up): post-treatment safety
           follow-up visit (ET/End of Treatment [EOT] +4 weeks) either in person or via telephone.
    
  